Abstract
Prostate cancer is the most common cancer affecting males in developed countries. It shows consistent evidence of familial aggregation, but the causes of this aggregation are mostly unknown. To identify common alleles associated with prostate cancer risk, we conducted a genome-wide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml). We analyzed these samples for 541,129 SNPs using the Illumina Infinium platform. Initial putative associations were confirmed using a further 3,268 cases and 3,366 controls. We identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X (P = 2.7 × 10−8 to P = 8.7 × 10−29). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Edwards, S.M. & Eeles, R.A. Unravelling the genetics of prostate cancer. Am. J. Med. Genet. C. Semin. Med. Genet. 129C, 65–73 (2004).
Amundadottir, L.T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652–658 (2006).
Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631–637 (2007).
Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645–649 (2007).
Freedman, M.L. et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl. Acad. Sci. USA 103, 14068–14073 (2006).
Haiman, C.A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638–644 (2007).
Gudmundsson, J. et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977–983 (2007).
Edwards, S.M. et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72, 1–12 (2003).
The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).
Easton, D.F. et al. Genome-wide association study identifies breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
Lilja, H. et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol. 25, 431–436 (2007).
Thomas, D.C., Haile, R.W. & Duggan, D. Recent developments in genomewide association scans: a workshop summary and review. Am. J. Hum. Genet. 77, 337–345 (2005).
Reeves, J.R., Dulude, H., Panchal, C., Daigneault, L. & Ramnani, D.M. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin. Cancer Res. 12, 6018–6022 (2006).
Steuber, T., Helo, P. & Lilja, H. Circulating biomarkers for prostate cancer. World J. Urol. 25, 111–119 (2007).
Steuber, T. et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int. J. Cancer 118, 1234–1240 (2006).
Cramer, S.D. et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Natl. Cancer Inst. 95, 1044–1053 (2003).
Lai, J. et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 28, 1032–1039 (2007).
Severi, G. et al. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol. Biomarkers Prev. 15, 1142–1147 (2006).
Kawa, S., Fujimoto, J., Tezuka, T., Nakazawa, T. & Yamamoto, T. Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling. Genes Cells 9, 219–232 (2004).
Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
Hidaka, K. et al. An adjacent pair of human NUDT genes on chromosome X are preferentially expressed in testis and encode two new isoforms of diphosphoinositol polyphosphate phosphohydrolase. J. Biol. Chem. 277, 32730–32738 (2002).
Eeles, R.A. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2, 9–15 (1999).
Giles, G.G. et al. Smoking and prostate cancer: findings from an Australian case-control study. Ann. Oncol. 12, 761–765 (2001).
Giles, G.G. et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol. Biomarkers Prev. 11, 549–553 (2002).
Severi, G. et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J. Natl. Cancer Inst. 95, 818–824 (2003).
MacInnis, R.J., English, D.R., Gertig, D.M., Hopper, J.L. & Giles, G.G. Body size and composition and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 12, 1417–1421 (2003).
Severi, G. et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 86–91 (2006).
Clayton, D. & Leung, H.T. An R package for analysis of whole-genome association studies. Hum. Hered. 64, 45–51 (2007).
Acknowledgements
We should like to thank all the individuals with prostate cancer and control men who took part in this study. This work was supported by Cancer Research UK Grant C5047/A3354. D.F.E. is a Principal Research Fellow of Cancer Research UK. J.L.H. is an Australia Fellow of the NHMRC. We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now known as Prostate UK), The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK, grants from the National Health and Medical Research Council, Australia (209057, 251533, 450104), VicHealth, The Cancer Council Victoria, The Whitten Foundation, and Tattersall's. We are grateful to the staff at Illumina: K.Viaud, C. McBride, J. Bernd, R. Morey, and the rest of the Illumina Genotyping Service Laboratory, and S. McBean, K. Cook, F. Amini, M.Laurent and M. Gibbs. We are also grateful to those at Tepnel Life Sciences for their help with this study: S. Doyle, A. Priest, A. Barlow, S. Howe and L. Holliday. We acknowledge the contribution of all members of the UKGPCS, BAUS and ProtecT study research groups, especially those listed in the supplementary material. We would like to acknowledge the help of N. Gauge, C. Bamber, S. Barrett and P. Kelham for sample collection and retrieval and L. Barakzai and P. Hamilton for assistance with preparing the manuscript. The ProtecT study is ongoing and is funded by the Health Technology Assessment Programme (projects 96/20/06, 96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison Arm for ProtecT) studies are supported by Department of Health, England; Cancer Research UK grant number C522/A8649, Medical Research Council of England grant number G0500966, ID 75466 and The NCRI, UK. The epidemiological data for ProtecT were generated though funding from the Southwest National Health Service Research and Development. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health of England.
Author information
Authors and Affiliations
Consortia
Contributions
R.A.E. and D.F.E. designed and directed the study and obtained financial support. Z.K-J. directed the genotyping of stage 2. D.F.E. and A.A.A.O. conducted the statistical analysis. J.M. and H.I.F. provided bioinformatics support. M.G. co-ordinated the UKGPCS. G.G.G., J.L.H. and D.R.E. directed the Australian studies. M.C.S. and G.S. co-ordinated the Australian studies. D.E.N., J.L.D. and F.C.H. directed the ProtecT study. The remaining authors collated samples and performed laboratory analyses. R.A.E. and D.F.E. drafted the manuscript.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1–8, Supplementary Note (PDF 365 kb)
Rights and permissions
About this article
Cite this article
Eeles, R., Kote-Jarai, Z., Giles, G. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40, 316–321 (2008). https://doi.org/10.1038/ng.90
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.90
This article is cited by
-
A revised nomenclature for the lemur family of protein kinases
Communications Biology (2024)
-
Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever
Nature Microbiology (2024)
-
Genetic preservation of SLC22A3 in the Admixed and Xhosa populations living in the Western Cape
Molecular Biology Reports (2023)
-
Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence
Scientific Reports (2022)
-
Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG
Nature Communications (2022)